Cargando…

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection

The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimeglio, Chloé, Migueres, Marion, Bouzid, Naémie, Chapuy-Regaud, Sabine, Gernigon, Caroline, Da-Silva, Isabelle, Porcheron, Marion, Martin-Blondel, Guillaume, Herin, Fabrice, Izopet, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506424/ https://www.ncbi.nlm.nih.gov/pubmed/36146626 http://dx.doi.org/10.3390/vaccines10091548

Ejemplares similares

Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Antibody titers and breakthrough infections with Omicron SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Antibody titers and protection against a SARS-CoV-2 infection
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays
por: Chapuy-Regaud, Sabine, et al.
Publicado: (2021)

One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection
por: Dimeglio, Chloé, et al.
Publicado: (2021)

Vectorial Release of Human RNA Viruses from Epithelial Cells
por: Chapuy-Regaud, Sabine, et al.
Publicado: (2022)

Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant
por: Migueres, Marion, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes
por: Nicot, Florence, et al.
Publicado: (2021)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Hepatitis E Pathogenesis
por: Lhomme, Sébastien, et al.
Publicado: (2016)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers
por: Migueres, Marion, et al.
Publicado: (2020)

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
por: Mykytyn, Anna Z., et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients
por: Bouzid, Donia, et al.
Publicado: (2023)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
por: Dimeglio, Chloé, et al.
Publicado: (2023)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics
por: Dimeglio, Chloé, et al.
Publicado: (2021)

Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens
por: Mansuy, Jean Michel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bci5kub4sm9paibm5mfs5npmug